ʻO ka maikaʻi o ka mea hoʻolako Peptide GLP-1: 2026 Kūʻai Kūʻai

Pane wikiwiki

Separate GLP-1 market hype from technical reality: the CoA fields, characterization data, and manufacturing discipline buyers should demand from peptide suppli…

He aha ka maikaʻi o ka mea hoʻolako GLP-1 e hōʻoia ai

E hoʻomaka me ke kiʻi mākeke, pōkole, no ka mea e wehewehe ana i ke kumu ʻaʻole i manaʻo ʻia ka nui o nā mea kūʻai aku ʻo GLP-1 peptide supplier.

Ua pau ka hemahema nui. Ua hōʻoia ka FDA i ka hemahema o ka tirzepatide i hoʻoholo ʻia i Dekemaba 2024 a me semaglutide i Pepeluali 2025, a me ka manaʻo hoʻokō no ka hoʻohui ʻana i kēlā mau molekala i hōʻeha ʻia i ka wā mua 2025. ʻO ka mea i hoʻoholo ʻole ʻo ia ke kaomi ʻana. ʻIkepili ʻoihana i paʻi ʻia ma 2026 kau i nā laina API peptide GLP-1 ʻAmelika ʻĀkau ma kahi o 90-95% hoʻohana, me ka puke horizons o 12 i 18 mahina a lōʻihi ka kali ʻana no nā mea komo hou. Ua hōʻike ʻia ʻo Drug Discovery News ma 2026 ʻoiai ua pau ka hemahema ʻōnaehana, paʻa paʻa ke kaulahao, me nā backorders intermittent a koi ʻoi aku ma mua o nā kuʻuna mōʻaukala.

ʻOi aku ka maikaʻi o ka nānā ʻana i hea ua neʻe ke kaohi. ʻAʻole hiki i ka Synthesis ke kaʻina palena wale. Hoʻomaʻemaʻe HPLC ma hope, resin a me ka mea hoʻoheheʻe, sterile hoʻopiha-hoʻopau, a ʻo ka hui ʻana o nā mea hana ke lawe nei i ka nui o ka ukana, he hoʻololi i ka bottleneck kēlā 2026 ʻO nā hiʻohiʻona nui o ka nānā ʻana i ka resin a me ka hoʻohana ʻana i ka solvent ma mua o ka manawa reactor. ʻO ka hoʻomaʻemaʻe kahi i lanakila a nalowale paha ka mana haumia, ʻo ia hoʻi, ʻoi aku ka maikaʻi o ka maikaʻi o ka lako GLP-1 i kēia lā ma kahi kokoke i ka palapala hōʻoia ma mua o ka reactor.

ʻO ia ka mea e hoʻopiʻi ai i kēia ʻatikala holoʻokoʻa: ʻAʻole hōʻike ka mākeke nui no nā mea GLP-1 i kahi mākeke nui no kūpono GLP-1 mea. ʻAʻole ʻōlelo ka loaʻa o ka leo e pili ana i ke ʻano kūpono o ka mea i mua ou, ina ua hoomaluia kona ano paakai, a i ʻole like ka hailona i loaʻa iā ʻoe me ka hailona i hoʻāʻo ʻia.

E hoʻomaka me ka pae e pono ai kāu hana

ʻO ka hapa maʻamau maʻamau ka hoʻohana ʻana i hoʻokahi maʻamau maʻamau i kēlā me kēia hihia hoʻohana. ʻAʻole pono ka pūʻolo hoʻokahi i kahi hoʻāʻo hoʻāʻo ʻimi a me kahi haʻawina hoʻonaʻauao IND, a ʻo ka hoʻopaʻa ʻana i nā mea hoʻomaʻamaʻa i kahi kikoʻī hoʻomohala e hoʻopau i ka waihona kālā ʻoiai ʻo ka paʻa ʻana i nā mea vivo i kahi papa screening one e hoʻopau i kahi haʻawina..

E hoʻohana i ka pae pūʻolo liʻiliʻi Manaʻo ikaika ʻīpuka paʻa
ʻImi ʻimi HPLC maemae ≥95%, ʻIkepili MS ≥98% me kahi chromatogram i hōʻike ʻia a me ke ʻano Ua hōʻoia ʻia ka ʻike e MS, ʻaʻole i helu ʻia
ʻO ka hoʻāʻo biochemical quantitative ≥98% HPLC, palapala hōʻoia hailona, ʻIkepili MS ≥99%, me ka ʻikepili counterion a me ke koena-solvent ana ka maemae, ʻaʻole i ʻōlelo ʻia he paepae
Moʻomeheu cell a me ka hana organoid Maluna, me ka endotoxin na LAL ʻO nā kikoʻī haʻahaʻa endotoxin me nā ʻāpana i ʻōlelo ʻia, me kahi moʻolelo haumia Hōʻike ʻia ka hopena Endotoxin ma EU/mg
In vivo haʻawina holoholona Maluna, me ka sterility kahi e pono ai ke ala Hiki ke hoʻopaʻa ʻia, counterion a me ka ʻikepili TFA, koena solvents, mōʻaukala nui Hoʻopili ʻia ka Sterility i kahi ala i ʻike ʻia
Hoʻomohala hoʻoponopono ʻia Nā ʻano hana i hōʻoia ʻia, hōʻailona orthogonal, ʻikepili kūpaʻa ʻO kahi pūʻolo CMC-style piha me nā ʻano hoʻokuʻu a paʻa Loaʻa nā moʻolelo hoʻokaʻawale a me ka hoʻololi ʻana

ʻAʻole ʻo Tiering kahi ala pōkole i ka haʻahaʻa haʻahaʻa. He ala ia e ʻike ai i nā hiʻohiʻona i hala / hāʻule no kāu hana a he ʻike ʻike. ʻO ka papahele no nā mea e komo ana i kahi ʻōnaehana ola he ʻike me ka maʻemaʻe a me ka endotoxin, a ʻaʻohe pono kumu kūʻai e ʻāpono i ka neʻe ʻana i lalo.

Palapala Peptide no ka hoʻopaʻa ʻana i nā koi: ka mea e pono ai ka palapala

ʻO ka palapala hōʻoia palekana he moʻolelo kikoʻī pūʻulu, ʻaʻole kahi palapala kūʻai. Pono e lawe i ka helu hailona i pai ʻia ma ka hue, nā ʻano hana i hana i kēlā me kēia hopena, nā waiwai i ana maoli ʻia, a me ka ʻike o ka hale hoʻokolohua. Hōʻike ka papa ma lalo i kēlā me kēia ʻano i ka mea e hōʻoiaʻiʻo ai a me kāna mau hōʻailona ʻole.

ʻAno Hoʻohuihui Peptide ʻO ka mea e hōʻoiaʻiʻo ai ʻano hana E ʻae iā t ʻO nā Peptides Synthetic paepae Hae ʻulaʻula
Ka nana aku ʻO ka mālama nui a me ka maikaʻi o ka lyophilization Nānā Kūlike, palapala ʻia ʻAʻole i hoʻopaʻa ʻia
ʻIkepili ʻO ka mea waiwai ka mole i manaʻo ʻia MS, ESI a MALDI paha; nānā ʻia vs theoretical mass Ma loko o ±1 Da o ka manaʻo He nuipa i helu ʻia me ka spectrum ʻole
Hoʻāʻo, o ka huina nui ʻO Peptide me ka counterion me ka wai HPLC Hōʻike ʻia ma ke ʻano he helu ʻAʻole
Hoʻāʻo, anhydrous a me ka counterion-free ʻO ka peptide hoʻoikaika kino Heluhelu mai ka luna Hōʻike ʻia ma ke ʻano he helu ʻAʻole - hiki ke ʻike ʻole ʻia ka ʻike
Maemae Hoʻomaʻemaʻe pili i nā mea haumia pili i ka peptide RP-HPLC, hōʻike ʻia ke ʻano a me ke kolamu ≥98%; ≥99% no ka hana quantitative a in vivo ʻO kahi ʻōlelo paepae e like me "ʻoi aku ma mua o 95%"
Nā mea pili Pilikino haumia RP-HPLC, hōʻoia orthogonal Hōʻike ʻia, hōʻike ʻole ʻia, a me nā mea haumia a pau i hōʻike ʻia Hoʻokahi pākēneka me ka haki ʻole
ʻAno wai ʻEhia ka nui o ka wai i kaupaona ʻia Karl Fischer Hōʻike ʻia, a haahaa ʻAʻole
ʻO ka ʻike kūʻē a me ka ʻike ʻAno paʻakai a me kona hāʻawi ʻana i ka nuipaʻa Ion chromatography a i ʻole like ʻIkepili me ka maʻiʻo nui ʻAʻole i hōʻike ʻia ke ʻano paʻakai
Nā mea hoʻoheheʻe koena Kaʻina hana koena Ma o ICH Q3C Hōʻike kūʻē i nā palena ʻAʻole i hoʻāʻo ʻia
Nā mea haumia Catalyst a me reagent lawe Ma o ICH Q3D Kahi e pili ana i ke ala ʻAʻole i loiloi ʻia
ʻO nā endotoxins bacteria Haawe pyrogen LAL a i ʻole rFC, no USP ⟨85⟩ Hōʻike ʻia ma EU/mg me ke ʻano ʻAʻohe hopena ma nā mea i manaʻo ʻia e injectable
Sterility a me ka bioburden ʻO ka hoʻohaumia microbial No USP ⟨71⟩ inā pili Hoʻopili ʻia i kahi ala i kapa ʻia He ʻōlelo hoʻolako ma kahi o kahi hoʻāʻo

ʻAʻole kūʻokoʻa ka panel. Hōʻike ia i ka mea i wehewehe ʻia e ka compendial framework no nā mea lāʻau peptide synthetic, a e holo ana ka pae ho'āʻo mai ke kaumaha molekala a me ka maʻemaʻe ma o ka ʻike, wai, paʻakai, sterility, a me ka pH. Inā makemake ʻoe i kahi kiʻi paʻa o ke ʻano o kēlā mau māla e like me kahi papa hoʻāʻo hana, nā mea hoʻāʻo i kūkulu ʻia kahi peptide CoA hoonoho ia lakou ma ke kaina.

ʻIkepili: mass spectrometry ka papahele, ʻaʻole ke kaupaku

ʻO ka hōʻoia ʻana o ke kaumaha molekala ma o ka spectrometry nuipaʻa ka mea liʻiliʻi loa no nā mea noiʻi. No nā hana kiʻekiʻe, a mahuahua ma ka manaʻolana ma mua o ke koho, mai ka LC-MS/MS ka hōʻoia pae kaʻina ma mua o ke ana intact-mass hoʻokahi.

ʻO ka hoʻomanawanui hana i ka alakaʻi ʻana i ka mea kūʻai aku ʻo ia ka mea i ʻike ʻia e like me ka manaʻo like ʻole 1 A. E noʻonoʻo i ka hana a me ka uhi ʻole. A 1 Loaʻa ka puka makani i kahi koena hewa i nā manawa he nui. ʻAʻole ia e hopu i kahi isomer kūlana me kahi ʻano like, a ʻaʻole ia e hopu i kahi hoʻololi i kau ʻia ma ke koena hewa. No nā peptides ma luna aʻe 2,000 A, a i ʻole ka lawe ʻana i nā hoʻololi maʻamau ʻole e like me ka cyclization, kāʻili ʻana, PEGylation, lipidation, aiʻole D-amino acids, ka 2026 ʻO ke alakaʻi hoʻolālā FDA no nā kaʻina hana loiloi no nā peptides synthetic e kuhikuhi ana i ka spectrometry lehulehu me ka hoʻokaʻawale ʻana no ka hōʻoia ʻana i ke kaʻina. He pae ʻokoʻa kēlā o ka hōʻike ma mua o ka nui paʻa, a ʻo ia ke kiʻekiʻe e pono ai kahi analogue GLP-1 i hoʻololi ʻia.

ʻO ka hoʻomaʻemaʻe HPLC me ka ʻike peptide: ka metric maikaʻi e alakaʻi hewa ana

ʻElua mau ana ʻokoʻa kēia, a ʻo ka hoʻohui ʻana iā lākou ʻo ia ke kuhi hewa ʻana i ka peptide sourcing.

ʻO ka maʻemaʻe HPLC kahi ratio. Hoʻohālikelike ia i ka piko peptide i hoʻopaʻa ʻia e kūʻē i nā mea haumia pili i ka peptide - nā kaʻina i ʻoki ʻia, nā huahana holoi, ʻano oxidized - a hōʻike i ka pākēneka o ka huina. ʻAʻole ia e ʻōlelo e pili ana i nā mea ʻē aʻe i loko o ka vial.

ʻO ka maʻiʻo peptide pūnaewele he nuipa. ʻO ka pauka peptide lyophilized ka peptide, he counterion e like me trifluoroacetate a i ʻole acetate, a me ka wai. Hāʻawi nā mea ʻekolu i ke kaumaha ma ke koena. E like me ka Kūkākūkā ʻo Faraday ka nānā ʻana o ka counterion a me nā hopena paʻakai ma nā peptides lōʻihi (2025) kau aku, ʻO ka pauka lyophilized ka mea maʻamau ka peptide me ka wai a me ka counterion, a ʻaʻole like ka maʻemaʻe me ka ʻike.

ʻAʻole ʻoluʻolu ka hopena kūpono. Ua hōʻike ʻia ʻelua vials ma 99% Hiki ke loaʻa i ka maʻemaʻe HPLC ka nui o nā peptide ikaika. Inā ʻoe e hoʻopaʻa a hoʻāʻo paha ma ke kaumaha, hele pololei ka ʻokoʻa i kāu hoʻokolohua. ʻO kēia ke kumu e hōʻike ai ka palapala hōʻoia i ʻelua manawa - hoʻokahi me ka counterion a me ka wai, i hoʻokahi helu ʻana i ka anhydrous a me ka counterion-free - a no ke aha i hōʻike ʻole ai kahi palapala hōʻike i ka maʻemaʻe wale nō i haʻi maoli iā ʻoe i kāu mea i kūʻai ai.

Counterion a me ka ukana TFA: ʻO ka hiʻohiʻona maikaʻi ka hapa nui o nā palapala hōʻoia i kāpae ʻia

Eia ka hakahaka nui loa, a oia ke kumu o keia pauku.

ʻO ka waikawa Trifluoroacetic ka mea hoʻohui ion-pairing maʻamau i ka hoʻomaʻemaʻe hoʻohuli, a hoʻomau ʻia i nā koena kumu o ka peptide. A laila hiki mai kekahi mea counterintuitive: ʻAʻole ʻike ʻia ʻo TFA ma ke ʻano he kiʻekiʻe haumia i ka hoʻomaʻemaʻe maʻemaʻe UV HPLC. Ua helu ʻia ka pākēneka maʻemaʻe e pili ana i nā ʻāpana pili i ka peptide. ʻAʻole ʻike ʻia ka counterion iā ia.

No laila hiki ke hōʻike ʻia kahi peptide ma 99% maʻemaʻe a lawe mau i kahi ukana counterion e hoʻololi i kāu mau hopena. ʻAʻole maʻalahi nā hopena i hōʻike ʻia.

ʻO ke koena TFA e hōʻemi i ka ʻike peptide net, no ka mea, noho ia i ka nuipaʻa ʻaʻole peptide. Ma luna aʻe 0.1% ma ke kaumaha e skews UV heluhelu ma 214 a 220 nm, me paʻi ʻia nā manaʻo o ka hoʻonui ʻana i ka manaʻo ma ka 5-40% ma muli o nā kūlana. Kāohi ia i ka ionization ma ka nuipa spectrometry ma o ke kinoea-phase ion pairing, he hopena i kākau ʻia ma ka hana peptide mass-spectrometry, ʻo ia ka mea hiki ke hoʻohaʻahaʻa i ka maʻemaʻe a i ʻole ka liʻiliʻi o ka laʻana. Hoʻololi ia i ka circular dichroism a me ka infrared spectra, He mea nui ia inā ʻoe e hoʻohana nei i ka nānā ʻana i ke ʻano. A hiki iā ia ke pale a hoʻoulu i ka hoʻonui ʻana o ka cell a hoʻopilikia i nā hoʻokolohua enzymatic, ka hana ʻana i nā ʻano like ʻole a me nā hōʻailona maikaʻi ʻole a hōʻemi ʻia i ka hana ma ke kelepona, e like me ka hōʻuluʻulu ʻia ma ke alakaʻi counterion no ka hoʻohana noiʻi.

ʻO ka palapala e pili ana i nā counterions i nā peptides pololei e pili ana i ke ala hele: ʻAʻole makemake ʻia ka ʻike TFA, no nā peptides i manaʻo ʻia no ka hana preclinical a me ka hana lapaʻau. Pono ka helu ʻana i kahi ala e hiki ke ʻike maoli iā ia - ion chromatography a i ʻole ¹⁹F NMR nā koho kūpono., me HPLC-ELSD a me ATR-FT-IR i hoʻohana ʻia i kekahi mau hoʻonohonoho. Kahi pilikia ka ukana TFA, ʻO ka hoʻololi ion i ka acetate a i ʻole HCl ka lāʻau maʻamau; hana kuʻikahi ma ka nānā ʻana a me ka hoʻololi ʻana o TFA kuhikuhi i ka hoʻololi ʻana o HCl me ka ʻole o ka hopena i ka maʻemaʻe peptide.

⚠️ ʻŌlelo Aʻo: A 99% ʻAʻole haʻi iā ʻoe ka helu maʻemaʻe HPLC e pili ana i ka ukana TFA. Inā ʻaʻole hōʻike ka palapala hōʻoia i ka ʻike a me ka ʻike, ʻAʻole hiki iā ʻoe ke helu i ka nui o ka peptide net - a inā hāʻawi kahi hōʻike kelepona i kahi hopena i manaʻo ʻole ʻia, ʻO ka mana TFA wale nō ma ka hoʻolaha like ʻana ke ala wikiwiki loa e ʻike ai inā ʻo ka counterion, ʻaʻole ka peptide, hana i ka hōʻailona.

Pilikino haumia: ʻaʻole kahi pākēneka he ʻike

ʻO ka helu maʻemaʻe he hōʻuluʻulu. ʻO ka mea āu e makemake ai he profile.

Ma ka liʻiliʻi, manaʻo i nā haumia i ʻike ʻia, nā mea haumia i ʻike ʻole ʻia, nā mea haumia ʻole i hōʻike ʻia, a he huina. USP ⟨1503⟩ ma nā ʻano maikaʻi o nā mea lāʻau peptide synthetic mālama i ka peptide maʻiʻo, hōʻike, mea pili, a me nā ho'āʻo kino e like me ke ʻano i hoʻonohonoho ʻia e kūkulu ʻia a puni, a ʻo kēlā me kēia haumia i ʻōlelo ʻia e lawe i kona palena ponoʻī me ka hoʻonā i hōʻike ʻia mai ka piko nui ma ka palena palena.

Ua neʻe ka papahele hoʻoponopono 2026. A 2026 loiloi ma ka Nūpepa o nā lāʻau lapaʻau hou e pili ana i nā manaʻo hoʻoponopono a me nā loiloi no ka maikaʻi o ka peptide ʻike ʻia nā haumia pili i ka peptide ma 0.10% pono e ʻike ʻia ka nui o ka lāʻau, me ka wehewehe ʻana i ka hana i manaʻo ʻia no nā haumia ma kēlā pae i nā peptides ma lalo 20 nā ʻakika amino. ʻO ke alakaʻi alakaʻi EMA i ka hoʻomohala ʻana a me ka hana ʻana i nā peptides synthetic, pono mai 1 Iune 2026, hoʻonohonoho i ka hōʻike ma luna 0.1%, ʻike ma luna 0.5%, a me ka pono ma luna 1.0%, i hoʻopaʻa ʻia i ka European Pharmacopoeia general monograph ma mua o ka mole liʻiliʻi ICH Q3A framework. Manaʻo ia i ke ʻano o nā haumia pili i ka peptide me ka hoʻohana ʻana i ʻelua mau ala orthogonal.

ʻAʻole paha ʻoe e waiho i kahi IND i kēia hapaha. ʻO ke kumu nui o kēia mau paepae ʻo ia ka wehewehe ʻana i ke ʻano o ke ʻano o ka haumia kūpono, a ʻo ia ka mea e ʻike ʻia e ka hui analytical o ka mea hoʻolako ma ke ʻano maʻamau. He palapala hōʻike e hōʻike ana i nā kaʻina i ʻoki ʻia, ʻano ʻano oxidized, nā palapala deamidate, epimers, a ʻokoʻa nā ʻano ʻano pili i ka hui ʻana, haʻi ʻia nā ʻano helu helu iā ʻoe ua hana ʻia ka hana analytical. He palapala hōʻike e hōʻike ana i hoʻokahi helu a ʻaʻohe mea ʻē aʻe e haʻi iā ʻoe ʻaʻole ia.

Hōʻoia ʻo Orthogonal: no ke aha i lawa ʻole ai kekahi ala

Hoʻokaʻawale ʻia ka HPLC ma ka hydrophobicity. ʻO nā haumia e like me ka hydrophobicity co-elute me ka piko nui a nalowale i ka helu maʻemaʻe.. ʻAʻole kēia he hypothetical - ʻo ia ke kumu maʻamau i hiki ai i kahi laʻana ke nānā maʻemaʻe ma kekahi ala a hāʻule i kekahi. ʻO ka 2026 ʻO ka manaʻolana o ʻelua mau ʻano orthogonal no ka ʻike ʻana i ka haumia aia maoli no ka mea he makapō kahi ala a ʻaʻohe ala e hōʻike ai..

ʻO ka orthogonality kūpono no kahi peptide e like me kēia: ʻo ke ʻano hana hoʻohuli ʻelua me ka hoʻohana ʻana i kahi kemika ʻokoʻa, no laila, loli nā ʻano co-elution; LC-MS a i ʻole LC-MS/MS no ka hōʻoia ʻana i ke ʻano o nā piko; ka nānā ʻana i ka waikawa amino no ka haku mele ʻana; chromatography hoʻokaʻawale nui i hui pū ʻia me ka hoʻopuʻi ʻana o nā kukui he nui kahi e hopohopo ai ka hoʻohui.; capillary electrophoresis no nā ʻano like ʻole e pili ana i ka uku. ʻO ka hoʻāʻo ʻana a me ka nānā ʻana i ka peptide uhi ʻia i ka hui ʻana o kēia mau ʻano hana i kahi kaila hana hōʻike piha.

E hahai pololei ana ka ninau hooia: ʻo ke ʻano ʻelua i hoʻohana ʻia, a he aha ka mea i hōʻike ʻia?

Endotoxin, sterility, a me ka bioburden

ʻAʻole koho ka hoʻāʻo Endotoxin no kekahi mea e hoʻopā i nā cell, organoids, a i ʻole he kumu hoʻohālike holoholona. Ua ana ia e ka Limulus amebocyte lysate assay i hoakakaia ma USP ⟨85⟩, ka ho'āʻo endotoxins bacteria, a i ʻole ma nā reagent recombinant ma lalo o ka mokuna USP hou, me nā hopena i hōʻike ʻia ma nā ʻāpana endotoxin no ka milligram a i ʻole ka vial. Nou ke kiko'ī, ʻaʻole ka mea hoʻolako: hoʻonoho i ka palena e pili ana i kāu ʻike hoʻāʻo a me ke ala i manaʻo ʻia. ʻO ka FDA alakaʻi e pili ana i nā kikoʻī endotoxins bacteria kūkākūkā i nā palena ma ke ala o ka hoʻokele, a ʻo ia nā wahi kuhikuhi no ka hoʻonohonoho ʻana i ke kaupaku kūpono ma mua o ka ʻae ʻana i kēlā me kēia helu i ʻike ʻia.

He ho'āʻo ʻokoʻa ka Sterility me kahi ākea ʻokoʻa. USP ⟨71⟩ uhi i ka sterility; Uhi ka USP ⟨85⟩ i ka endotoxin. Hoʻopili pinepine ʻia lākou i nā mea hoʻolako a pane lākou i nā nīnau like ʻole. He mea nui ka hoʻāʻo ʻana i ka sterility no in vivo, hiki ke injectable, a i ʻole nā ​​mea i hoʻoponopono ʻia a ʻaʻole pili i kahi peptide noiʻi lyophilized maʻamau e hana hou ʻia no ka hoʻohana in vitro - akā ke koi ʻia ka mea hoʻolako., pono ka inoa o ke kuleana ma mua o ka hoʻokō ʻana i kahi kūlana.

Pono ka ʻikepili hāʻule ma ʻaneʻi. Loaʻa i ka hoʻāʻo ʻana i nā mea noiʻi noiʻi hale hana palapala ʻia ka endotoxin ma luna o nā paepae pae noiʻi ma ka ʻaneʻane 18% o nā laʻana i hoʻāʻo ʻia, me ka hoʻohaumia metala kaumaha ma luna o nā palena USP ma kahi ʻāpana liʻiliʻi. Inā ʻaʻole ʻoe e hoʻāʻo no ka endotoxin, ke hilinaʻi nei ʻoe i kahi manawa ʻehā a i ʻelima mau manawa i mālama pono ʻia - a ʻaʻole kēlā mau pilikia āu e makemake ai ma lalo o kahi haʻawina ʻeono pule..

He aha ka hana kemika GLP-1 i ka pilikia maikaʻi

Nā koina noiʻi maʻamau-peptide ma lalo o ka lawelawe ʻana i nā mea GLP-1, a he mea pono ke kikoo aku i ke kumu. ʻO ka pilikia o ka maikaʻi o kēia papa mole ke koʻikoʻi ma nā wahi ʻehā, paʻakikī kēia mau mea a pau me nā ʻano hana i hoʻohana ʻia e kahi palapala maʻamau.

ʻO ka lipidation kikoʻī pūnaewele a me nā isomers like-mass

ʻO ka hoʻolālā o Semaglutide e pili ana i kahi kaulahao ʻaoʻao momona-acid i hoʻopili ʻia ma kahi lysine kikoʻī, a hilinaʻi ʻo tirzepatide i ka hoʻokomo pono ʻana i ka lipid-linker. Hoʻopili i ka lysine hewa, aiʻole ma ka N-terminus, hiki ke hana i kahi isomer kūlana me ka nuipaʻa paʻa like. ʻAʻole ʻokoʻa ka hōʻoia intact-mass iā lākou. ʻO ka hopena kemika he mole me ke ʻano like, ke kaumaha molekala like ma ka palapala, a me nā ʻano hoʻopaʻa ʻokoʻa like ʻole.

Lawe pū nā kaulahao ʻaoʻao Semaglutide i kā lākou mau papa haumia - mono-AEEA, tri-AEEA, a me nā ʻano β-alanine - pono e hoʻomalu ʻia i ka wā o ka hoʻohui ʻana i nā kaulahao ʻaoʻao e pale i ka mea hope.

He pololei ka implication: no kahi peptide GLP-1 lipidated, pono ka ʻike intact-mass akā ʻaʻole lawa. ʻO ka hōʻoia ʻana i ka hoʻololi ʻana e noho ana ma kahi e pono ai ka nānā ʻana i ka fragmentation a i ʻole ka palapala peptide, ʻaʻole he helu lehulehu. Hana ʻia ʻo Peptide

Nā koena maʻamau ʻole, nā holoi ʻana, a me nā ʻoki ʻana

Aib — 2-aminoisobutyric acid — he koena i hooleleia ʻoi aku ka mālie o nā kāne ma mua o nā waikawa amino canonical ma muli o kāna gem-dimethyl alpha-carbon. Pono nā protocols no ia mea i nā manawa hoʻolōʻihi ʻia a i ʻole ka hui ʻana pālua e hiki ai i ka hoʻohui piha ʻana, a ʻo ka hoʻohui ʻole ʻana e hoʻopuka i ka des-Aib a me nā ʻano ʻano pōkole ʻē aʻe. No ka mea, ʻaʻole ʻo ʻAib kekahi o nā koena maʻamau he iwakālua, ʻAʻole ʻike pono ka loiloi amino acid maʻamau iā ia; Hana ʻo MS a me ka palapala peptide.

A laila aia ka pilikia hōʻiliʻili. Hoʻohui ʻia ʻo Tirzepatide ma kahi ākea 39 nā pōʻaiapuni, a ʻoi aku ka liʻiliʻi o kēlā me kēia pōʻai inefficiency pūhui ma kēlā mau ʻanuʻu he nui i loko o kahi ʻohana o ka holoi ʻana i ka iwi kuamoʻo a me ka ʻoki ʻana. ʻO nā diastereomers Aib-kūlana ma nā kūlana i wehewehe ʻia he papa haumia i manaʻo ʻia ma mua o ka pīhoihoi. ʻO ka hoʻokumu ʻana o Diketopiperazine kahi pilikia kūikawā no nā kaʻina me ka N-terminus pale ʻole.

ʻAno ʻano hana E ʻae Hae ʻulaʻula
Lipidation kikoʻī pūnaewele Māhele MS a i ʻole ka palapala peptide Hoʻololi i ke koena i manaʻo ʻia Nuipa paʻa wale nō
Aib a me nā koena maʻamau ʻole MS, palapala palapala peptide Hoʻohui piha, pololei stereochemistry Ua hilinaʻi wale ʻia ka ʻike ʻana i ka waikawa amino
Holoi a me ka ʻoki ʻana RP-HPLC me ka hōʻoia orthogonal Nā palena pākahi me ka huina ʻAʻole i hōʻike ʻia ma ke ʻano he papa
Diastereomers ʻO ka hoʻokaʻawale ʻana o Chiral a i ʻole ka hoʻonā kiʻekiʻe inā pili palena i kuhikuhi ʻia ʻAʻole i loiloi ʻia
Diketopiperazine RP-HPLC Ma lalo o ka palena ʻAʻole mālama ʻia

ʻO ka hui ʻana a me ka bottleneck hoʻomaʻemaʻe

ʻO nā peptides lipidated he hydrophobic, a me nā peptides hydrophobic pili iā ia iho. Hōʻike ʻia kēlā hui pilikino i ka wā synthesis, māwae, hoʻopaʻa ʻana, waihona, a me ka hoomaemae ana. Hoʻohaʻahaʻa ia i nā hua ʻike, hana ia i ka chromatography hiki ʻole ke wānana, a hiki iā ia ke hoʻomau ma ke ʻano he ʻano kaumaha molekala kiʻekiʻe a ʻaʻole pono ke ʻano hoʻomaʻemaʻe hoʻohuli ʻia.. ʻO ka chromatography hoʻokaʻawale nui ke ʻano orthogonal e hopu ai.

ʻO ka hoʻomaʻemaʻe kahi e lilo ai kēia i mea pipiʻi. Ke piʻi nei ka lōʻihi o ke kaulahao a me ka hydrophobicity, ʻO ka peptide i hoʻopaʻa ʻia a me kona mau haumia kokoke loa e loaʻa i ka ʻano hana hoʻohuli like, no laila ʻaʻole lawa ka hana HPLC hoʻomākaukau hoʻokahi. Pono pinepine nā peptide lipidated lōʻihi i ka hoʻomaʻemaʻe multistep me nā ʻanuʻu orthogonal - hoʻololi ion, SEK, ka ua, a i ʻole nanofiltration. Hōʻike ke ala kalepa ʻo Tirzepatide i ka hopena hui: kahi hoʻolālā paʻa paʻa a me ka hoʻolālā wai i kūkulu ʻia mai nā ʻāpana ʻāpana i hoʻomaʻemaʻe ʻia, ka mea e hoʻonui ai i ka helu o nā kiko e paʻa ai ke kūlike.

No ka mea kuai, ʻO ka lawe ʻana, ʻo ka mea hoʻolako hiki ke hana i kahi peptide laina pōkole hiki ʻole ke hāʻawi i kahi analogue lipidated GLP-1 mau., a ʻaʻole e ʻike mau ʻia ka ʻokoʻa ma kahi pākēneka maʻemaʻe.

ʻO ka mea hoʻolako waiwai waiwai peptide: nā hōʻike hana ma hope o ka palapala hōʻoia

ʻO kahi palapala hōʻoia o ka nānā ʻana he mea hoʻopuka. ʻO ke aʻo ʻana e hoʻopuka ai he hana, a hiki ke hōʻoia ʻia ke kaʻina hana - ma o nā moʻolelo i mālama ʻia e kahi mea hoʻolako kūpono. ʻO kēia ka ʻāpana o ka hōʻailona mea kūʻai aku ʻaʻole i uhi ʻia kahi hōʻailona hōʻoia.

Ka hoʻomalu i ka hana a me nā moʻolelo pūʻulu

Manaʻo i nā kiko mana i wehewehe ʻia ma ka synthesis, ka hoomaemae ana, kānana, hoʻomaloʻo, a me ka paʻi ʻana, kēlā me kēia me nā pae hoʻohālike i ʻōlelo ʻia, nā hopena i hoʻopaʻa ʻia, a me kahi pūlima loiloi. E manaʻo i kahi moʻolelo puʻupuʻu haku e wehewehe ana i ke kaʻina hana a me kahi moʻolelo puʻupuʻu i hoʻokō piha ʻia no ka ʻāpana kikoʻī āu e kūʻai nei, e hōʻike ana i nā mea i hoʻohana ʻia, mea hoʻomaopopo, pūlima mea hoʻohana, hōʻailona manawa, hua mai, nā hopena i ka hana, kekahi hana hou a hana hou, a me ka hoʻokuʻu QA hope. Pono e hana ʻia nā moʻolelo i ka wā e hana ai ka hana, ʻaʻole i kūkulu hou ʻia ma hope - ka GMP framework no nā lāʻau lapaʻau ikaika Pono e hoʻopaʻa ʻia nā hana e pili ana i ka maikaʻi i ka manawa a me nā ʻano koʻikoʻi e noiʻi ʻia me nā hopena i kākau ʻia..

ʻaʻe, KAPA, a hoʻololi i ka mana

E noi i ka log deviation, ka papa hana hoʻoponopono a pale, a me nā hōʻoia kūpono o kēia manawa. Hoʻopaʻa ʻia kahi haʻalele me ke kumu ʻole i hoʻopaʻa ʻia a ʻaʻole hoʻopaʻa ʻia kahi hōʻoia kūpono; he pilikia i nana ole ia. E nīnau pehea e mālama ʻia ai nā hopena o waho a me nā hanana hoʻohaumia, a nīnau i ka mea i hana ʻia i ka manawa hope loa.

ʻO ka mana hoʻololi ka hapa ʻē aʻe. Pono ʻo ICH Q7 i kahi ʻōnaehana maʻamau no ka loiloi ʻana i nā loli e pili ana i ka hana a me ka hoʻomalu ʻana i kahi kikowaena waena a i ʻole API, me nā hoʻololi i nā mea maka, ʻano hana, mea lako, nā mea hana, lako polokalamu, a me nā kikoʻī, me ka loiloi pilikia a me ka hōʻoia hou ʻana inā pono. He aha ka cGMP i uhi maoli i ka hana peptide hoʻonui i ka traceability waiwai, palapala pūʻulu, hoʻopaʻapaʻa ʻana, a me ke ala hooia mai ka hoʻomaka ʻana i nā mea a hiki i ka hue i hoʻopau ʻia. Inā hoʻololi ka mea hoʻolako i kahi mea hoʻolako resin, he protocol hui, a i ʻole ka laulima hoʻomaʻemaʻe, makemake ʻoe e ʻike i ka loiloi hopena a me ka ʻikepili hoʻohālikelike - no ka mea, ʻo ia hoʻololi ke ʻano e lilo ai nā ʻāpana maikaʻi o ka makahiki i hala i kēia makahiki..

Ka pono o ka lako a me ka hoomalu kaiapuni

Pono pono nā lako i hoʻohana ʻia i ka hana ʻana, hoʻopili ʻia, a mālama ʻia. E nānā i ka hoʻokomo, hana hana, a me ka hōʻoia hana no nā lako koʻikoʻi a me nā pono hana, me ka calibration, mālama, a me ka ʻikepili hoʻomaʻemaʻe a paʻa paha. ʻO kahi mea hana i hana i kāu palapala hōʻoia me ka ʻole o kahi moʻolelo calibration o kēia manawa he kumu nāwaliwali ia no kēlā palapala.

ʻO ka mana kaiapuni kahi i kākoʻo ʻia ai kahi koi e ka ʻikepili a i ʻole. I loko o kahi lumi hoʻomaʻemaʻe papa, ʻo ia hoʻi ka nānā ʻana i nā ʻāpana ola a hiki ʻole ke ola, kaomi ʻokoʻa, mahana wela, haʻahaʻa, nā moʻolelo hoʻomaʻemaʻe a disinfection, i ho'ākāka 'ia nā palena maka'ala a me nā hana, a me ka nānā 'ana i ke au i ka manawa. ʻO ka loiloi trend ka ʻāpana i hoʻokuʻu ʻia. He kiʻi paʻi kiʻi kiʻi kiʻi kiʻi helu ʻāpana pākahi hoʻokahi; ʻO kahi pakuhi e hele nei me nā huakaʻi i ʻimi ʻia he hōʻike ia o kahi kaiapuni i hoʻomalu ʻia. Hana ʻia-kaiapuni wehewehe i ke ʻano o ka hoʻonohonoho ʻia ʻana o ka zoning a me ka nānā ʻana ma waena o kahi keʻena peptide i hoʻohui ʻia, He kuhikuhi kūpono ia no ke ʻano o ka ʻikepili ma mua o kou ʻae ʻana i kahi koi kaiapuni.

E hōʻoia ana i ke alahaka mg-a-kg

Hoʻemi ʻia ka pilikia o ka hoʻonui ʻana no ka mea hāʻule mālie. He kaʻina hana i hōʻoia ʻia ma 50 ʻAʻole hōʻike ʻo mg e pili ana i kahi 500 g holo. ʻO ka mea e hoʻololi ai ʻaʻole ia ka meaʻai akā nā ʻāpana kaʻina hana koʻikoʻi, ka hui ʻana a me ka hoʻoili nui ʻana, ka haawe hoomaemae, a me ka pōʻaiapili lyophilization.

E noi i kahi hōʻike hōʻoia kaʻina hana a i ʻole hōʻike hoʻonui e hōʻike ana i ka hoʻohālikelike ma waena o nā unahi: ʻaoʻao haumia, hua mai, ka maemae, a me nā ʻāpana kaʻina hana koʻikoʻi ma kēlā me kēia pālākiō, me ka ʻikepili analytical e kākoʻo i ka hoʻohālikelike. Kahi e hilinaʻi ai ka synthesis i nā ʻāpana ʻāpana, e like me ka nui o nā molekala GLP-1 lōʻihi, manaʻo i ka ʻikepili hoʻohālikelike ma ka pae ʻāpana pū kekahi. ʻO nā ala kūpono no nā kaʻina hana paʻakikī e hoʻohui hāʻawi i ka manaʻo o ke ʻano o ka hoʻolālā ala a me nā hoʻoponopono hoʻomaʻemaʻe ke ʻano ke kūʻē ke kaʻina i nā kūlana maʻamau, ʻo ia ka nīnau kūpono ma hope inā hiki i kahi mea hoʻolako ke hoʻopaʻa i kahi kikoʻī i ka piʻi ʻana o ka leo.

Pehea e hōʻoia ai i kahi mea hoʻolako ma mua o kou hoʻopaʻa ʻana

Lilo nā mea a pau i luna i noi hoʻoponopono. E hoʻopuka ma mua o kou kau ʻana i ke kauoha, ʻaʻole ma hope o ka pau ʻana o ka haʻawina.

Nā palapala e noi ai, a he aha ka hōʻole ʻana iā ʻoe

E noi i ka palapala hōʻoia hailona ma mua o ke kūʻai ʻana. E hōʻoia i ka helu hailona ma ka palapala hōʻoia e like me ka helu hailona ma ka vial a ma nā palapala hoʻouna. E hōʻoia i ka inoa o ka palapala hōʻoia i ke keʻena hoʻokolohua me nā kikoʻī pili ʻike, a hiki ke hoʻopaʻa ʻia kahi koi ʻae. E noi i ka ʻikepili maka ma hope o ka hōʻuluʻulu manaʻo: ka chromatogram me ka manawa paʻa a me ka ʻikepili wahi kiʻekiʻe, ka nuipaʻa spectrum me ka nānā ʻana e kūʻē i ka nuipaʻa theoretical.

He diagnostic ka manawa. ʻO ka mea hoʻolako e hoʻopuka i ka palapala hōʻoia i hoʻohālikelike ʻia i loko o hoʻokahi lā a ʻelua paha ia ma ka faila no kēlā hailona. ʻO ka mea hoʻolako e makemake i hoʻokahi pule e ʻimi iā ia maʻamau ʻaʻole loaʻa kahi no kēlā ʻāpana, a ʻo ka mea e hiki mai ana he laʻana.

Ka papa inoa hae-ula

hōʻailona He aha ka manaʻo He aha ka nīnau
ʻAʻohe palapala i loaʻa ma mua o ke kūʻai ʻana Hana ʻia ka palapala ma hope o ke kūʻai ʻana "E hoʻouna i ka palapala kikoʻī kikoʻī no ka ʻāpana āu e hoʻouna ai."
Palapala maʻamau a maʻamau paha ʻAʻohe hōʻike hoʻāʻo pūʻulu “No ka helu hea kēia palapala hōʻoia?”
ʻŌlelo maʻemaʻe paepae ("ʻoi aku ma mua o 95%") ʻAʻohe waiwai i ana ʻia “He aha ka maʻemaʻe i ana ʻia, a he aha ke ʻano?”
ʻAʻohe ʻikepili MS, HPLC wale nō ʻAʻole hōʻoia ʻia ka ʻike "E hoʻouna i ka spectrum me ka nānā ʻana a me ka theoretical mass."
ʻAʻole i hōʻike ʻia ke ʻano paʻakai ʻAʻole ʻike ʻia ka nui peptide net “He aha ka counterion, a he aha ka mea i loko?”
ʻO ka palapala hōʻoia ma mua o ʻumikūmālua mahina no ka waihona o kēia manawa Hoʻohana ʻia ka ʻikepili paʻa i ka waihona hou “He aha ka lā hoʻāʻo no kēia hailona?”
ʻAʻohe hale hoʻokolohua i kapa ʻia Loaʻa paha nā hopena i loko o ka hale a hiki ʻole ke hōʻoia ʻia "ʻO ka hale hana i hana i ka hoʻāʻo?”
Ma lalo o ka mākeke Hoʻopunipuni, underdosed, a i ʻole nā ​​mea i pani ʻia "He aha ka wehewehe ʻana i ka ʻokoʻa?”
ʻO ka haʻalele ʻana i nā moʻolelo puʻupuʻu a i ʻole nā ​​haʻalele ʻAʻole paha nā moʻolelo "E hoʻouna i ka moʻolelo puʻupuʻu i hoʻokō ʻia a me ka log deviation."
Hāʻawi ʻia ka hoʻāʻo i loko o ka hale ma ke ʻano he koho wale nō ʻAʻohe ala hōʻoia kūʻokoʻa “E kākoʻo anei ʻoe i ka hoʻāʻo hou ʻana o nā ʻaoʻao ʻekolu?”

ʻElua o kēia mau mea e pono ai ke koʻikoʻi no ka mea ʻo lākou ka poʻe kūʻai i kamaʻilio pinepine iā lākou iho. A 2022 Kemika Analytical ke aʻo ʻana i nā peptides i loaʻa i ke kālepa loaʻa kēlā 23% ʻaʻole i hoʻokō i kā lākou mau kikoʻī maʻemaʻe i ʻōlelo ʻia, a he hōʻailona maikaʻi ke kumukūʻai ma ke ala like: ʻO kahi ʻokoʻa ma lalo o ka median no ka hui like ʻaʻole ia he hana pono, he huahana okoa. A ʻo ka paʻakai paʻakai ʻaʻole ia he pepa pepa - me ka ʻole, ʻO ka helu āu e kaupaona nei ʻaʻole paha ka nui o ka peptide āu i manaʻo ai.

ʻO ka hoʻāʻo hou ʻana o ka ʻaoʻao ʻekolu a me nā helu helu

ʻO ka hoʻāʻo hou kūʻokoʻa kāu hōʻoia wale nō ʻaʻole i hilinaʻi ʻia i nā ʻōlelo ponoʻī a ka mea hoʻolako, a he kūpono ke kumukūʻai ma kekahi mea e komo ana i kahi ʻōnaehana ola. Holo ia ma ka loaʻa, a mālama i ka makemake o ka mea hoʻolako e kākoʻo iā ia ma ke ʻano he ʻāpana o ka hoʻoholo hoʻoholo ma mua o ka hoʻoholo ʻana. Nānā FDA o nā keʻena peptide ua haʻi pinepine i nā moʻolelo pūʻulu nalo a me ka mana kūpono ʻole, ka maemae, a me ka ho'āʻo sterility, ʻo ia ka hoʻāʻo hou kūʻokoʻa i hoʻolālā ʻia e pani.

ʻAʻole i loaʻa mai nā hōʻike ikaika loa mai kahi ʻāpana hoʻokahi, ʻoiai. E noi i nā helu helu mōʻaukala: manaʻo, hoʻokaʻawale maʻamau, a me ka pākēneka pili maʻamau no ka maʻemaʻe, ʻike ʻike, a me nā mea haumia nui ma nā ʻāpana he nui. Hoʻokahi palapala hala e hōʻike ana i hoʻokahi hailona i hala. ʻO ka hāʻawi paʻa ʻana i nā ʻāpana he ʻumi he hōʻike ia o kahi kaʻina hana i hoʻomalu ʻia - a ʻo ia ka ʻokoʻa ma waena o ka mea hoʻolako i loaʻa pono i hoʻokahi manawa a me kahi mea hoʻolako i loaʻa pono ia..

No ke kōkua: ʻO ka noi helu hailona ka nīnau hōʻailona kiʻekiʻe loa ma ka loiloi holoʻokoʻa. E pane koke nā mea hoʻolako i ka pākēneka RSD ma nā hailona, no ka mea, ua loaʻa iā lākou ka ʻikepili. ʻO nā mea hoʻolako ʻole e pane me ka palapala hoʻokahi. Hōʻike ka pane i kekahi mea pono, a ua hoʻohana ʻoe i hoʻokahi leka uila no ka loaʻa ʻana.

Nīnau pinepine

Pehea wau e ʻike ai inā he kūpono ka palapala hōʻoia peptide?

E nānā i ʻekolu mau mea paʻakikī e hoʻopunipuni pū: pili ka helu hailona i ka hue a me nā palapala hoʻouna; inoa ka palapala hōʻoia i kahi keʻena hoʻāʻo nona ka ʻike a me ka ʻae āu e hiki ai ke hōʻoia; a loaʻa iā ia ka ʻikepili analytical maka - he chromatogram me ka ʻike manawa paʻa a me ka ʻike wahi kiʻekiʻe, a me kahi kikoʻī nui me ka nānā ʻana e kūʻē i ka nuipaʻa kumu. ʻO ka palapala hōʻoia i nele i kekahi o nā mea ʻekolu he koi ia ma mua o kahi moʻolelo. ʻO ka palapala hōʻike e hōʻike ana i ka paepae ma kahi o ka waiwai i ana ʻia ʻo ia ka ʻōlelo hoʻokahi maopopo loa.

He aha ka maʻemaʻe e loaʻa i nā mea noiʻi GLP-1?

No ka hana ʻimi maʻamau, Maʻemaʻe HPLC ma luna a i ʻole 95% me ka ʻike MS ka papahele. No nā hoʻokolohua biochemical quantitative a me nā mea like, 98% a i ʻole ma luna me kahi palapala kikoʻī kikoʻī ʻo ia ke kūlana hana, a 99% ke ulu nei ka manao. No ka hana in vivo, 99% me ka ho'āʻo endotoxin, a me sterility kahi e pono ai ke ala. ʻAʻole lawa ka maʻemaʻe wale - a 99% ʻAʻole i haʻi ʻia ke kiʻi maʻemaʻe i hui pū ʻia me kahi ukana counterion i hōʻike ʻole ʻia i ka nui o ka peptide i loko o ka hue..

ʻO ka maʻemaʻe o ka HPLC ka like me ka peptide content?

ʻAʻole, a hiki ke ana ka okoa. ʻO ka maʻemaʻe HPLC ka ratio o ka peptide i hoʻopaʻa ʻia i nā haumia pili i ka peptide. ʻO ka maʻiʻo peptide ka nui o ka peptide ikaika, koe ka counterion a me ka wai. Aia i loko o kahi pauda lyophilized nā mea ʻekolu, no laila, hiki i nā hue ʻelua i ka maʻemaʻe like ke loaʻa i nā nui o ka peptide. ʻO ia ke kumu e hōʻike ai ka palapala hōʻoia i ka hoʻāʻo ʻana i ka nui o ka nui a me ka helu anhydrous a me ka counterion-free, a no ke aha ke kūʻai ʻana ma ke kaumaha nui me ka ʻole o kēlā ʻikepili e hoʻolauna i kahi hewa i ʻike ʻole ʻia.

No ke aha he mea nui ka TFA i ka mea peptide?

ʻO TFA ka mea hoʻohui ion-pairing i hoʻohana ʻia i ka hoʻomaʻemaʻe hoʻohuli ʻia, a paʻa mau ia i nā koena kumu o ka peptide. ʻAʻole i helu ʻia he haumia pili i ka peptide i ka nānā ʻana maʻemaʻe HPLC maʻamau, peʻe ia ma hope o kahi helu maʻemaʻe kiʻekiʻe i ka wā e hōʻemi ana i ka ʻike peptide net. Ma luna aʻe 0.1% ma ke kaumaha, ua skews ia i ka helu UV, kaohi i ka ionization ma ka nuipa spectrometry, hoʻololi i ka CD a me IR spectra, a hiki ke hoʻokaʻawale i nā hōʻike ma ke kelepona ma kēlā me kēia ʻaoʻao. Kahi mea nui, e hoʻohālikelike iā ia - ʻo ka chromatography ion a me ¹⁹F NMR nā ʻano hana kūpono - a noʻonoʻo i ka hoʻololi ion i ka acetate a i ʻole HCl.

Nā ʻanuʻu aʻe

E lawe i hoʻokahi mea hoʻolako ikaika a hoʻopuka i ka noi loiloi i kēia pule: palapala hōʻoia hailona me ka hōʻike ʻana i ke ʻano, chromatogram maka a me spectrum, ʻike kūʻē a me ka ʻike, ʻano wai, endotoxin i EU/mg, executed batch record, hoʻokaʻawale a me ka log CAPA, log hoʻololi-mana, nā moʻolelo hoʻonaʻauao lako, nā ʻano nānā kaiapuni, a me nā helu helu me ka pakeneka RSD. A laila e hoʻopili i kahi puka maʻalahi: ʻO kēlā me kēia hiʻohiʻona he ʻīpuka paʻakikī no kāu pae a hiki ʻole ke hana ʻia he pilikia i hoʻoholo ʻole ʻia, ʻaʻole kahi hakahaka liʻiliʻi. ʻO ka pilikia i hoʻoholo ʻole ʻia ma ke komo ʻana i kahi ʻōnaehana ola e hoʻopau i ka loiloi.

E hoʻomau ka mākeke i nā peptides GLP-1. ʻO ka nīnau hōʻoia - inā hiki i ka mea hoʻolako ke hōʻoia i ka mea a lākou i hoʻouna ai - ʻo ia ka mea e hoʻokaʻawale i kahi kaulahao lako hoʻohana mai kahi lehulehu..

Hoʻopili kēia ʻatikala i ka maikaʻi o ka waiwai a me ke ʻano analytical no nā mea kūʻai mai noiʻi a hoʻomohala. ʻAʻole ia he ʻōlelo aʻo lapaʻau, ʻaʻole kuhikuhi i ke alakaʻi, a ʻaʻole ia he pani no ka loiloi kikoʻī o kāu ʻāpana ponoʻī a i ʻole loiloi hoʻoponopono.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana